A Pharmacokinetic Study of VCT220 in Particicants With Hepatic Injury and Normal Hepatic Function

Summary

This is an open-label, non-randomized study to assess how VCT220 is absorbed, distributed, metabolized, and eliminated after a single oral dose. The study includes three groups: subjects with mild hepatic impairment (Child-Pugh Class A), subjects with moderate hepatic impairment (Child-Pugh Class B), and healthy subjects matched by gender, age, and body mass index (BMI). It will also explore the relationship between baseline liver function measures and the pharmacokinetic (PK) parameters of VCT220, to support appropriate dosing recommendations for patients with liver impairment.

Timeline

Start

2025-04-18

Primary completion

2025-07-15

Completion

2025-07-25

Drugs

Indications